hydroxyzine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diphenylmethyl piperazine derivatives 1400 68-88-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydroxyzine pamoate
  • hydroxizine
  • hydroxyzin
  • hydroxyzyne
  • tranquizine
  • hydroxyzine
  • hydroxyzine hydrochloride
  • hydroxyzine dihydrochloride
  • hydroxyzine HCl
A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
  • Molecular weight: 374.91
  • Formula: C21H27ClN2O2
  • CLOGP: 4
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 35.94
  • ALOGS: -3.61
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
75 mg O
75 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 700 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 15.24 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 12, 1956 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 819.29 10.13 880 57649 131009 50415586
Intentional overdose 335.42 10.13 387 58142 62117 50484478
Intentional self-injury 294.26 10.13 231 58298 22881 50523714
Toxicity to various agents 288.70 10.13 708 57821 211791 50334804
Urticaria 211.14 10.13 464 58065 129097 50417498
Pruritus 206.59 10.13 758 57771 282810 50263785
Drug abuse 199.42 10.13 293 58236 59553 50487042
Cardio-respiratory arrest 134.18 10.13 231 58298 53661 50492934
Poisoning 128.30 10.13 110 58419 12319 50534276
Respiratory arrest 127.09 10.13 165 58364 29844 50516751
Pemphigus 124.63 10.13 3 58526 120163 50426432
Contraindicated product administered 120.88 10.13 15 58514 148943 50397652
Treatment failure 113.81 10.13 13 58516 137624 50408971
Synovitis 112.34 10.13 8 58521 123857 50422738
Joint swelling 111.98 10.13 73 58456 245213 50301382
Rheumatoid arthritis 105.80 10.13 51 58478 202499 50344096
Systemic lupus erythematosus 105.20 10.13 18 58511 140604 50405991
Poisoning deliberate 104.82 10.13 81 58448 7831 50538764
Glossodynia 100.52 10.13 9 58520 115560 50431035
Drug dependence 95.37 10.13 116 58413 19643 50526952
Anxiety 90.56 10.13 426 58103 177180 50369415
Cardiac arrest 90.07 10.13 256 58273 83395 50463200
Suicide attempt 89.52 10.13 190 58339 51542 50495053
Drug intolerance 83.77 10.13 78 58451 219026 50327569
Dermatitis atopic 81.14 10.13 51 58478 3535 50543060
Anticholinergic syndrome 80.43 10.13 40 58489 1755 50544840
Arthropathy 76.17 10.13 44 58485 157862 50388733
Burning mouth syndrome 66.05 10.13 23 58506 400 50546195
Somnolence 65.05 10.13 352 58177 154633 50391962
Suicidal ideation 65.04 10.13 175 58354 55210 50491385
Therapeutic product effect decreased 64.07 10.13 39 58490 136011 50410584
Abdominal discomfort 62.93 10.13 107 58422 231534 50315061
Electrocardiogram QT prolonged 61.99 10.13 165 58364 51721 50494874
Wound 61 10.13 23 58506 105771 50440824
Skin plaque 59.27 10.13 53 58476 6275 50540320
Irritability 56.99 10.13 111 58418 28315 50518280
Drug reaction with eosinophilia and systemic symptoms 55.78 10.13 110 58419 28314 50518281
Hepatic enzyme increased 54.75 10.13 47 58482 137333 50409262
Psoriasis 53.86 10.13 189 58340 68811 50477784
Eczema 53.46 10.13 95 58434 22607 50523988
Infusion related reaction 52.10 10.13 72 58457 169485 50377110
Chronic spontaneous urticaria 50.54 10.13 20 58509 504 50546091
Angioedema 50.36 10.13 125 58404 37551 50509044
Urticaria thermal 49.79 10.13 15 58514 160 50546435
Maternal exposure during pregnancy 46.96 10.13 70 58459 159708 50386887
Prescription form tampering 45.59 10.13 19 58510 549 50546046
Scratch 45.37 10.13 41 58488 4921 50541674
Chemical submission 44.38 10.13 14 58515 176 50546419
Overdose 44.20 10.13 230 58299 99497 50447098
Victim of chemical submission 43.78 10.13 15 58514 248 50546347
Helicobacter infection 42.85 10.13 4 58525 49698 50496897
Alopecia 42.08 10.13 144 58385 244903 50301692
Bradypnoea 39.69 10.13 31 58498 3043 50543552
Drug ineffective 39.61 10.13 689 57840 818644 49727951
Lower respiratory tract infection 38.62 10.13 32 58497 95169 50451426
Suspected suicide 37.13 10.13 38 58491 5319 50541276
Depression 37.10 10.13 322 58207 165101 50381494
Asphyxia 36.71 10.13 38 58491 5389 50541206
Alcoholism 36.55 10.13 23 58506 1597 50544998
Rash maculo-papular 35.19 10.13 88 58441 26553 50520042
Drug screen positive 34.88 10.13 30 58499 3372 50543223
Intentional product misuse 34.74 10.13 126 58403 46608 50499987
Mastocytosis 33.88 10.13 15 58514 504 50546091
Hallucination, gustatory 33.11 10.13 9 58520 64 50546531
Urinary retention 33.02 10.13 85 58444 26105 50520490
Multiple drug therapy 32.81 10.13 23 58506 1914 50544681
Mixed liver injury 32.51 10.13 29 58500 3422 50543173
Long QT syndrome 32.13 10.13 27 58502 2940 50543655
Drug hypersensitivity 31.00 10.13 434 58095 250576 50296019
Allergy test positive 30.67 10.13 13 58516 392 50546203
Faecal vomiting 29.28 10.13 14 58515 563 50546032
Serotonin syndrome 28.91 10.13 78 58451 24635 50521960
Infection 28.75 10.13 103 58426 172851 50373744
Musculoskeletal stiffness 26.72 10.13 69 58460 128412 50418183
Metabolic acidosis 26.62 10.13 102 58427 38723 50507872
Insomnia 26.48 10.13 314 58215 174551 50372044
Agitation 26.37 10.13 127 58402 53257 50493338
Parkinsonism 26.15 10.13 41 58488 8806 50537789
Perfume sensitivity 25.63 10.13 13 58516 595 50546000
Miosis 25.62 10.13 34 58495 6276 50540319
Folliculitis 25.30 10.13 7 58522 39218 50507377
Impaired healing 25.29 10.13 26 58503 69760 50476835
Withdrawal syndrome 24.18 10.13 59 58470 17531 50529064
General physical health deterioration 23.55 10.13 85 58444 142349 50404246
Muscle injury 23.24 10.13 7 58522 37104 50509491
Disturbance in attention 23.10 10.13 84 58445 31102 50515493
Diet failure 22.67 10.13 6 58523 38 50546557
Labile hypertension 22.60 10.13 11 58518 460 50546135
Coma 22.36 10.13 127 58402 56752 50489843
Psychotic symptom 21.96 10.13 15 58514 1197 50545398
Altered state of consciousness 21.58 10.13 65 58464 21845 50524750
Panic attack 21.58 10.13 60 58469 19282 50527313
Dermatitis exfoliative generalised 21.35 10.13 22 58507 3104 50543491
Neutropenia 20.87 10.13 94 58435 147871 50398724
Blood immunoglobulin E increased 20.61 10.13 19 58510 2340 50544255
Nodular rash 20.39 10.13 8 58521 197 50546398
Product dose omission issue 20.35 10.13 312 58217 183526 50363069
Interstitial lung disease 20.20 10.13 19 58510 53157 50493438
Lymphomatoid papulosis 20.20 10.13 7 58522 120 50546475
Joint ankylosis 20.19 10.13 12 58517 752 50545843
Hereditary angioedema 20.09 10.13 28 58501 5414 50541181
Pancreatitis 20.06 10.13 100 58429 42514 50504081
Sleep disorder 20.01 10.13 124 58405 57159 50489436
Plasma cell myeloma 19.45 10.13 6 58523 31316 50515279
Distributive shock 19.14 10.13 12 58517 828 50545767
Off label use 19.11 10.13 411 58118 474015 50072580
Decreased eye contact 19.10 10.13 8 58521 234 50546361
Migraine 18.69 10.13 150 58379 75130 50471465
Photosensitivity reaction 18.49 10.13 44 58485 12867 50533728
Depressed level of consciousness 18.48 10.13 113 58416 51840 50494755
Arthralgia 18.26 10.13 378 58151 438324 50108271
Binge eating 18.24 10.13 9 58520 388 50546207
Cold agglutinins positive 18.10 10.13 5 58524 38 50546557
Sensitivity to weather change 18.00 10.13 28 58501 5973 50540622
Toxic skin eruption 17.94 10.13 40 58489 11211 50535384
Red blood cell sedimentation rate increased 17.62 10.13 6 58523 29410 50517185
Akathisia 17.55 10.13 33 58496 8196 50538399
Aggression 17.47 10.13 59 58470 21057 50525538
Skin lesion 17.33 10.13 69 58460 26658 50519937
Burnout syndrome 17.20 10.13 7 58522 190 50546405
Anaemia 17.15 10.13 198 58331 252258 50294337
Feeling abnormal 17.11 10.13 221 58308 125271 50421324
Papule 17.01 10.13 23 58506 4322 50542273
Hyperleukocytosis 16.91 10.13 9 58520 455 50546140
Pneumonia 16.65 10.13 323 58206 378078 50168517
Derailment 16.62 10.13 5 58524 53 50546542
Dementia 16.27 10.13 48 58481 15949 50530646
Emotional distress 16.24 10.13 71 58458 28592 50518003
Wound secretion 16.17 10.13 21 58508 3796 50542799
Lip erythema 16.09 10.13 6 58523 128 50546467
Wrong technique in device usage process 16.09 10.13 17 58512 2469 50544126
Mast cell activation syndrome 15.92 10.13 8 58521 359 50546236
Temperature intolerance 15.79 10.13 30 58499 7509 50539086
Irritable bowel syndrome 15.62 10.13 22 58507 51419 50495176
Hip arthroplasty 15.35 10.13 8 58521 30421 50516174
Blood cholesterol decreased 15.01 10.13 10 58519 766 50545829
Mydriasis 14.98 10.13 36 58493 10591 50536004
Injection site mass 14.96 10.13 46 58483 15634 50530961
Drug withdrawal syndrome 14.88 10.13 63 58466 25018 50521577
Linear IgA disease 14.81 10.13 12 58517 1242 50545353
Discomfort 14.59 10.13 70 58459 108310 50438285
Gastrointestinal disorder 14.55 10.13 58 58471 94398 50452197
Stomatitis 14.51 10.13 64 58465 101280 50445315
Superior mesenteric artery syndrome 14.41 10.13 5 58524 86 50546509
Affect lability 14.36 10.13 32 58497 8966 50537629
Apallic syndrome 14.31 10.13 9 58520 624 50545971
Post-traumatic stress disorder 14.21 10.13 21 58508 4282 50542313
Asthma 14.21 10.13 162 58367 89175 50457420
Initial insomnia 14.15 10.13 23 58506 5092 50541503
Tonsillar hypertrophy 14.01 10.13 10 58519 856 50545739
Accidental overdose 13.95 10.13 52 58477 19481 50527114
Postural orthostatic tachycardia syndrome 13.95 10.13 10 58519 862 50545733
Dermatitis 13.77 10.13 42 58487 14209 50532386
Cholestasis 13.69 10.13 62 58467 25339 50521256
Exposure during pregnancy 13.62 10.13 83 58446 120932 50425663
C-reactive protein increased 13.58 10.13 36 58493 66438 50480157
Talipes 13.55 10.13 12 58517 1402 50545193
Urticaria chronic 13.46 10.13 8 58521 501 50546094
Skin discolouration 13.44 10.13 74 58455 32683 50513912
Superior sagittal sinus thrombosis 13.41 10.13 9 58520 698 50545897
Knee arthroplasty 13.39 10.13 13 58516 35833 50510762
Illness 13.31 10.13 60 58469 24480 50522115
Alpha 1 globulin increased 13.27 10.13 5 58524 110 50546485
Restless arm syndrome 13.25 10.13 4 58525 43 50546552
Transverse sinus thrombosis 13.25 10.13 8 58521 516 50546079
Pleural effusion 13.20 10.13 49 58480 81405 50465190
Fatigue 13.16 10.13 677 57852 706924 49839671
Ehlers-Danlos syndrome 13.02 10.13 5 58524 116 50546479
Hallucination, olfactory 13.01 10.13 6 58523 222 50546373
Granulomatous liver disease 13.00 10.13 9 58520 734 50545861
Eyelid haemangioma 12.90 10.13 3 58526 10 50546585
Hypercreatininaemia 12.80 10.13 7 58522 374 50546221
Exposure via ingestion 12.79 10.13 16 58513 2787 50543808
Micrognathia 12.70 10.13 6 58523 235 50546360
Hallucination, visual 12.56 10.13 45 58484 16537 50530058
Social anxiety disorder 12.46 10.13 7 58522 394 50546201
Dependence 12.45 10.13 13 58516 1862 50544733
Pain of skin 12.39 10.13 28 58501 7919 50538676
Malignant neoplasm progression 12.38 10.13 39 58490 68085 50478510
Breast adenoma 12.35 10.13 4 58525 55 50546540
Swelling 12.33 10.13 161 58368 200711 50345884
Retrograde amnesia 12.30 10.13 7 58522 404 50546191
Multiple fractures 12.27 10.13 25 58504 6586 50540009
Alpha 2 globulin increased 12.24 10.13 5 58524 137 50546458
Fat necrosis 12.19 10.13 8 58521 597 50545998
Respiratory depression 12.18 10.13 36 58493 11974 50534621
Erythema 12.05 10.13 237 58292 146177 50400418
Substance abuse 12.03 10.13 19 58510 4105 50542490
Iron deficiency 11.88 10.13 23 58506 5839 50540756
Pneumonitis 11.86 10.13 10 58519 29500 50517095
Negative thoughts 11.76 10.13 9 58520 857 50545738
Bruxism 11.76 10.13 16 58513 3024 50543571
Nightmare 11.63 10.13 43 58486 16043 50530552
Herpes zoster meningoencephalitis 11.56 10.13 6 58523 288 50546307
Pulmonary fibrosis 11.50 10.13 7 58522 24430 50522165
Bronchial wall thickening 11.41 10.13 9 58520 896 50545699
Drug interaction 11.41 10.13 307 58222 199314 50347281
Dystonia 11.39 10.13 35 58494 11891 50534704
Vascular stent thrombosis 11.38 10.13 9 58520 900 50545695
Atrial fibrillation 11.34 10.13 70 58459 101675 50444920
Gastrointestinal ischaemia 11.10 10.13 5 58524 175 50546420
Blood pressure decreased 11.07 10.13 106 58423 55803 50490792
Ventricular fibrillation 11.04 10.13 32 58497 10527 50536068
Occipital neuralgia 11.03 10.13 6 58523 317 50546278
Formication 10.92 10.13 17 58512 3629 50542966
Tremor 10.84 10.13 190 58339 114713 50431882
Osteonecrosis of jaw 10.81 10.13 13 58516 32513 50514082
Breath odour 10.80 10.13 10 58519 1238 50545357
Loss of personal independence in daily activities 10.79 10.13 43 58486 70007 50476588
Bipolar disorder 10.75 10.13 24 58505 6733 50539862
Product use in unapproved indication 10.74 10.13 191 58338 115628 50430967
Sinusitis 10.72 10.13 136 58393 170422 50376173
Acidosis 10.70 10.13 31 58498 10196 50536399
Febrile bone marrow aplasia 10.70 10.13 23 58506 6288 50540307
Gastrointestinal haemorrhage 10.68 10.13 46 58483 73275 50473320
Tardive dyskinesia 10.63 10.13 25 58504 7254 50539341
Neuropathy peripheral 10.56 10.13 67 58462 96690 50449905
Hypertriglyceridaemia 10.47 10.13 21 58508 5470 50541125
Mucosal inflammation 10.46 10.13 19 58510 40123 50506472
Hypertonic bladder 10.43 10.13 15 58514 2985 50543610
Eosinophilia 10.41 10.13 46 58483 18606 50527989
Crying 10.39 10.13 49 58480 20367 50526228
Activation syndrome 10.39 10.13 5 58524 204 50546391
Staphylococcal skin infection 10.37 10.13 8 58521 771 50545824
Thrombocytopenia 10.35 10.13 96 58433 127577 50419018
Oedema mouth 10.33 10.13 13 58516 2277 50544318
Peripheral circulatory failure 10.29 10.13 7 58522 555 50546040
Therapeutic product effect incomplete 10.17 10.13 63 58466 91452 50455143
Stress 10.16 10.13 101 58428 53692 50492903

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 567 10.92 560 28353 89686 29455928
Toxicity to various agents 317.79 10.92 590 28323 173071 29372543
Drug abuse 142.42 10.92 269 28644 79614 29466000
Intentional overdose 95.17 10.92 150 28763 38378 29507236
Respiratory arrest 89.32 10.92 118 28795 25715 29519899
Pruritus 80.39 10.92 274 28639 116575 29429039
Poisoning 73.77 10.92 68 28845 9925 29535689
Cardio-respiratory arrest 67.15 10.92 151 28762 50450 29495164
Coma 66.68 10.92 130 28783 39320 29506294
Dermatitis atopic 59.01 10.92 33 28880 2186 29543428
Suicidal behaviour 58.57 10.92 28 28885 1337 29544277
Overdose 55.55 10.92 188 28725 79631 29465983
Ventricular tachyarrhythmia 52.43 10.92 17 28896 281 29545333
Urticaria 50.35 10.92 142 28771 54518 29491096
Parasomnia 48.86 10.92 17 28896 352 29545262
Drug reaction with eosinophilia and systemic symptoms 48.21 10.92 93 28820 27899 29517715
Cardiac arrest 48.05 10.92 188 28725 85403 29460211
Bradypnoea 44.09 10.92 28 28885 2343 29543271
Hyperthermia 43.79 10.92 50 28863 9380 29536234
Ureteric compression 43.04 10.92 13 28900 168 29545446
Suspected suicide 36.97 10.92 31 28882 3989 29541625
Priapism 35.98 10.92 32 28881 4456 29541158
Intentional self-injury 35.68 10.92 52 28861 12409 29533205
Chemical submission 35.02 10.92 8 28905 30 29545584
Toxic epidermal necrolysis 34.60 10.92 63 28850 18090 29527524
Electrocardiogram QT prolonged 34.36 10.92 95 28818 36042 29509572
Alcoholism 34.18 10.92 25 28888 2636 29542978
Exposure via ingestion 30.65 10.92 21 28892 1997 29543617
Personal relationship issue 29.87 10.92 11 28902 270 29545344
General physical health deterioration 29.77 10.92 34 28879 102823 29442791
Somnolence 28.49 10.92 173 28740 93782 29451832
Psoriasis 27.99 10.92 82 28831 32145 29513469
Abnormal sleep-related event 27.96 10.92 12 28901 444 29545170
Face oedema 26.70 10.92 41 28872 10242 29535372
Clonus 25.37 10.92 20 28893 2358 29543256
Haematoma muscle 24.82 10.92 14 28899 943 29544671
Sensory integrative dysfunction 24.70 10.92 6 28907 31 29545583
Non-cardiogenic pulmonary oedema 24.31 10.92 12 28901 615 29544999
Postmortem blood drug level 24.30 10.92 8 28905 139 29545475
Emotional disorder of childhood 24.24 10.92 6 28907 34 29545580
Dermatitis exfoliative generalised 23.79 10.92 21 28892 2895 29542719
Autism spectrum disorder 23.66 10.92 18 28895 2014 29543600
Anticholinergic syndrome 22.97 10.92 13 28900 881 29544733
Electrocardiogram QRS complex prolonged 22.92 10.92 24 28889 4086 29541528
Pyelocaliectasis 22.90 10.92 14 28899 1095 29544519
Drug dependence 22.82 10.92 58 28855 20923 29524691
Tachyphrenia 22.22 10.92 14 28899 1155 29544459
Febrile bone marrow aplasia 21.51 10.92 31 28882 7320 29538294
Myocardial infarction 21.04 10.92 48 28865 110248 29435366
Respiratory depression 20.95 10.92 43 28870 13480 29532134
Stereotypy 20.86 10.92 11 28902 648 29544966
Tachycardia 20.48 10.92 131 28782 72279 29473335
Rash 20.08 10.92 278 28635 189541 29356073
Disease progression 19.70 10.92 31 28882 81885 29463729
Mumps 19.62 10.92 6 28907 81 29545533
Miosis 19.50 10.92 31 28882 7978 29537636
Echolalia 19.36 10.92 8 28905 269 29545345
Drug ineffective 18.99 10.92 246 28667 362924 29182690
Mental disorder 18.79 10.92 40 28873 12865 29532749
Bladder dilatation 18.43 10.92 13 28900 1295 29544319
Dry skin 18.07 10.92 57 28856 23250 29522364
Agitation 17.84 10.92 98 28815 51206 29494408
Drug screen positive 17.38 10.92 20 28893 3781 29541833
Fixed eruption 17.06 10.92 12 28901 1190 29544424
Agoraphobia 16.95 10.92 7 28906 235 29545379
Intentional product misuse 16.94 10.92 73 28840 34588 29511026
Psychotic disorder 16.92 10.92 51 28862 20303 29525311
Suicidal ideation 16.88 10.92 73 28840 34643 29510971
Drug withdrawal syndrome 16.81 10.92 47 28866 17937 29527677
Injection site reaction 16.66 10.92 35 28878 11153 29534461
Infective pulmonary exacerbation of cystic fibrosis 16.38 10.92 25 28888 6211 29539403
Disturbance in attention 16.25 10.92 52 28861 21372 29524242
Eosinophilia 16.10 10.92 53 28860 22108 29523506
Tremor 16.08 10.92 125 28788 73413 29472201
Rash erythematous 16.05 10.92 52 28861 21510 29524104
Serotonin syndrome 15.62 10.92 45 28868 17467 29528147
Hypercapnic coma 15.58 10.92 6 28907 167 29545447
Generalised oedema 15.56 10.92 34 28879 11131 29534483
Administration related reaction 15.46 10.92 5 28908 82 29545532
Diarrhoea infectious 15.35 10.92 8 28905 460 29545154
Eczema 14.81 10.92 38 28875 13788 29531826
Neurodevelopmental disorder 14.67 10.92 7 28906 333 29545281
C-reactive protein increased 14.66 10.92 13 28900 44250 29501364
Neonatal respiratory distress 14.59 10.92 8 28905 510 29545104
Anaemia 14.58 10.92 126 28787 200825 29344789
Pneumonia 14.54 10.92 223 28690 319949 29225665
Thyroiditis acute 14.31 10.92 5 28908 105 29545509
Prothrombin time ratio decreased 14.30 10.92 7 28906 352 29545262
Acute generalised exanthematous pustulosis 14.13 10.92 22 28891 5561 29540053
Speech disorder developmental 14.11 10.92 13 28900 1894 29543720
Victim of crime 14.05 10.92 7 28906 366 29545248
Throat tightness 14.01 10.92 25 28888 7066 29538548
Rheumatoid arthritis 13.93 10.92 7 28906 32145 29513469
Meningioma 13.72 10.92 11 28902 1329 29544285
Sinus tachycardia 13.71 10.92 39 28874 15030 29530584
Faecal vomiting 13.62 10.92 7 28906 391 29545223
Victim of homicide 13.60 10.92 5 28908 122 29545492
Cerebrovascular accident 13.46 10.92 35 28878 76876 29468738
Diarrhoea 13.37 10.92 237 28676 332461 29213153
Pupillary reflex impaired 13.23 10.92 11 28902 1398 29544216
Mixed dementia 12.86 10.92 6 28907 271 29545343
Neurosis 12.86 10.92 5 28908 143 29545471
Acute respiratory distress syndrome 12.53 10.92 50 28863 22885 29522729
Arthritis allergic 12.43 10.92 3 28910 15 29545599
Suicide attempt 12.42 10.92 66 28847 34044 29511570
Cerebral disorder 12.02 10.92 13 28900 2295 29543319
Chronic spontaneous urticaria 12.02 10.92 4 28909 72 29545542
Anion gap 11.99 10.92 8 28905 728 29544886
Post-traumatic stress disorder 11.89 10.92 11 28902 1611 29544003
Atrial fibrillation 11.85 10.92 58 28855 105588 29440026
Cardiac failure congestive 11.82 10.92 37 28876 76544 29469070
Injection site mass 11.77 10.92 20 28893 5435 29540179
Aplastic anaemia 11.77 10.92 24 28889 7486 29538128
Anxiety 11.56 10.92 131 28782 85234 29460380
Pharyngeal dyskinesia 11.46 10.92 3 28910 22 29545592
Alcohol withdrawal syndrome 11.43 10.92 10 28903 1363 29544251
Aspirin-exacerbated respiratory disease 11.28 10.92 6 28907 360 29545254
Drug diversion 11.25 10.92 8 28905 807 29544807
Neuropathy peripheral 11.18 10.92 34 28879 70993 29474621

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1318.52 10.20 1442 71999 222972 64202319
Toxicity to various agents 580.72 10.20 1277 72164 362236 64063055
Intentional overdose 307.53 10.20 442 72999 89502 64335789
Drug abuse 275.61 10.20 520 72921 131854 64293437
Urticaria 248.38 10.20 530 72911 146787 64278504
Pruritus 225.42 10.20 824 72617 311576 64113715
Respiratory arrest 205.85 10.20 277 73164 52708 64372583
Poisoning 205.01 10.20 182 73259 21697 64403594
Intentional self-injury 198.62 10.20 203 73238 28841 64396450
Cardio-respiratory arrest 185.73 10.20 371 73070 98022 64327269
Cardiac arrest 123.39 10.20 421 73020 153643 64271648
Dermatitis atopic 103.64 10.20 61 73380 3815 64421476
Anticholinergic syndrome 101.57 10.20 53 73388 2616 64422675
Suicide attempt 94.62 10.20 233 73208 70774 64354517
Drug reaction with eosinophilia and systemic symptoms 94.62 10.20 198 73243 54019 64371272
Poisoning deliberate 93.69 10.20 95 73346 13363 64411928
Somnolence 90.11 10.20 464 72977 203181 64222110
Synovitis 86.45 10.20 7 73434 99083 64326208
Joint swelling 83.99 10.20 73 73368 215309 64209982
Rheumatoid arthritis 82.48 10.20 42 73399 164252 64261039
Bradypnoea 78.42 10.20 57 73384 5102 64420189
Chemical submission 75.93 10.20 22 73419 206 64425085
Drug dependence 75.65 10.20 136 73305 33176 64392115
Overdose 73.66 10.20 368 73073 159198 64266093
Coma 70.58 10.20 240 73201 87375 64337916
Suspected suicide 65.62 10.20 64 73377 8590 64416701
Contraindicated product administered 64.77 10.20 21 73420 107808 64317483
Burning mouth syndrome 62.92 10.20 23 73418 471 64424820
Electrocardiogram QT prolonged 60.83 10.20 214 73227 79234 64346057
Eczema 60.79 10.20 116 73325 29604 64395687
Anxiety 60.16 10.20 416 73025 202233 64223058
Chronic spontaneous urticaria 55.21 10.20 21 73420 482 64424809
Skin plaque 54.87 10.20 59 73382 8881 64416410
Treatment failure 54.08 10.20 33 73408 116783 64308508
Pemphigus 53.75 10.20 4 73437 60697 64364594
Pericarditis 52.93 10.20 5 73436 62511 64362780
Drug intolerance 52.54 10.20 83 73358 187909 64237382
Arthropathy 50.87 10.20 38 73403 120929 64304362
Serotonin syndrome 50.31 10.20 127 73314 39155 64386136
Alcoholism 50.23 10.20 37 73404 3380 64421911
Urticaria thermal 49.60 10.20 15 73426 165 64425126
Suicidal behaviour 48.73 10.20 34 73407 2853 64422438
Intentional product misuse 48.01 10.20 186 73255 72109 64353182
Glossodynia 45.77 10.20 9 73432 64687 64360604
General physical health deterioration 44.29 10.20 105 73336 204320 64220971
Systemic lupus erythematosus 43.39 10.20 17 73424 77595 64347696
Asphyxia 41.76 10.20 53 73388 9513 64415778
Therapeutic product effect decreased 41.51 10.20 42 73399 115309 64309982
Parasomnia 41.48 10.20 17 73424 478 64424813
Ureteric compression 40.94 10.20 13 73428 170 64425121
Faecal vomiting 40.86 10.20 21 73420 1004 64424287
Disturbance in attention 40.83 10.20 121 73320 40953 64384338
Drug hypersensitivity 40.75 10.20 432 73009 237383 64187908
Psoriasis 40.13 10.20 175 73266 71528 64353763
Suicidal ideation 40.02 10.20 166 73275 66376 64358915
Dermatitis exfoliative generalised 39.79 10.20 41 73400 5875 64419416
Exposure via ingestion 38.57 10.20 37 73404 4865 64420426
Hyperthermia 38.56 10.20 66 73375 15484 64409807
Miosis 37.88 10.20 60 73381 13206 64412085
Lower respiratory tract infection 36.93 10.20 32 73409 94582 64330709
Anaemia 36.88 10.20 266 73175 378414 64046877
Victim of chemical submission 34.65 10.20 13 73428 287 64425004
Multiple drug therapy 34.48 10.20 25 73416 2229 64423062
Scratch 33.28 10.20 39 73402 6450 64418841
Hallucination, gustatory 33.13 10.20 9 73432 65 64425226
Hepatic enzyme increased 32.96 10.20 61 73380 129882 64295409
Agitation 32.74 10.20 192 73249 88175 64337116
Wound 32.18 10.20 24 73417 76453 64348838
Priapism 31.30 10.20 30 73411 3940 64421351
Angioedema 30.94 10.20 146 73295 61675 64363616
Pneumonia 30.55 10.20 451 72990 559125 63866166
Rash maculo-papular 30.41 10.20 120 73321 46906 64378385
Drug screen positive 30.33 10.20 35 73406 5694 64419597
Helicobacter infection 30.13 10.20 4 73437 38358 64386933
Pyelocaliectasis 30.07 10.20 16 73425 822 64424469
Drug withdrawal syndrome 29.98 10.20 91 73350 31200 64394091
Allergy test positive 29.95 10.20 13 73428 423 64424868
Irritability 29.87 10.20 101 73340 36645 64388646
Mastocytosis 29.61 10.20 13 73428 435 64424856
Respiratory depression 29.19 10.20 75 73366 23368 64401923
Insomnia 28.72 10.20 348 73093 197488 64227803
Infusion related reaction 28.54 10.20 94 73347 164373 64260918
Altered state of consciousness 28.06 10.20 101 73340 37801 64387490
Abdominal discomfort 27.17 10.20 111 73330 182211 64243080
Distributive shock 26.88 10.20 20 73421 1855 64423436
Long QT syndrome 26.54 10.20 31 73410 5108 64420183
Drug ineffective 26.20 10.20 743 72698 839504 63585787
Personal relationship issue 25.29 10.20 9 73432 170 64425121
Perfume sensitivity 24.83 10.20 13 73428 646 64424645
Depression 24.71 10.20 318 73123 182973 64242318
Psychotic symptom 24.56 10.20 20 73421 2118 64423173
Urinary retention 24.48 10.20 116 73325 49085 64376206
Maternal exposure during pregnancy 24.32 10.20 45 73396 95839 64329452
Eosinophilia 23.69 10.20 96 73345 37980 64387311
Dry skin 23.57 10.20 118 73323 51043 64374248
Injection site reaction 23.20 10.20 110 73331 46554 64378737
C-reactive protein increased 22.80 10.20 46 73395 94863 64330428
Diet failure 22.76 10.20 6 73435 38 64425253
Neuropathy peripheral 22.65 10.20 64 73377 117461 64307830
Tachyphrenia 22.50 10.20 18 73423 1858 64423433
Injection site mass 22.28 10.20 56 73385 17214 64408077
Arthritis allergic 21.98 10.20 5 73436 15 64425276
Febrile bone marrow aplasia 21.88 10.20 43 73398 11212 64414079
Mixed liver injury 21.79 10.20 29 73412 5452 64419839
Labile hypertension 21.46 10.20 11 73430 523 64424768
Atrial fibrillation 21.42 10.20 111 73330 170978 64254313
Accidental overdose 21.19 10.20 85 73356 33472 64391819
Infection 20.41 10.20 125 73316 184755 64240536
Fixed eruption 20.30 10.20 18 73423 2141 64423150
Musculoskeletal stiffness 20.29 10.20 72 73369 123134 64302157
Prothrombin time ratio decreased 20.23 10.20 12 73429 761 64424530
Binge eating 20.23 10.20 10 73431 440 64424851
Urticaria chronic 20.21 10.20 10 73431 441 64424850
Neutropenia 20.19 10.20 175 73266 239449 64185842
Panic attack 20.13 10.20 61 73380 20892 64404399
Sensitivity to weather change 20.05 10.20 31 73410 6683 64418608
Disease progression 20.03 10.20 88 73353 141592 64283699
Impaired healing 19.58 10.20 24 73417 60449 64364842
Tachycardia 19.52 10.20 258 73183 149321 64275970
Feeling abnormal 19.37 10.20 235 73206 133367 64291924
Drug resistance 19.11 10.20 8 73433 35094 64390197
Diarrhoea 19.09 10.20 653 72788 722051 63703240
Mydriasis 19.08 10.20 49 73392 15263 64410028
Haematoma muscle 18.99 10.20 16 73425 1777 64423514
Acute respiratory distress syndrome 18.79 10.20 91 73350 38844 64386447
Plasma cell myeloma 18.69 10.20 15 73426 46060 64379231
Withdrawal syndrome 18.59 10.20 64 73377 23428 64401863
Postmortem blood drug level 18.49 10.20 8 73433 258 64425033
Cerebral infarction 18.43 10.20 12 73429 41032 64384259
Renal impairment 18.40 10.20 85 73356 134932 64290359
Affect lability 18.27 10.20 35 73406 8955 64416336
Pleural effusion 18.26 10.20 78 73363 126481 64298810
Therapeutic product effect incomplete 18.04 10.20 59 73382 103423 64321868
Toxic epidermal necrolysis 18.03 10.20 87 73354 37079 64388212
Haemoglobin decreased 18.01 10.20 139 73302 194924 64230367
Malignant neoplasm progression 17.90 10.20 67 73374 112804 64312487
Victim of crime 17.75 10.20 9 73432 418 64424873
Joint ankylosis 17.71 10.20 11 73430 758 64424533
Pulmonary fibrosis 17.62 10.20 6 73435 29872 64395419
Electrocardiogram QRS complex prolonged 17.58 10.20 35 73406 9209 64416082
Thrombocytopenia 17.31 10.20 167 73274 223634 64201657
Red blood cell sedimentation rate increased 17.19 10.20 7 73434 31228 64394063
Abnormal sleep-related event 17.15 10.20 11 73430 802 64424489
Nodular rash 17.08 10.20 8 73433 312 64424979
Cold agglutinins positive 17.05 10.20 5 73436 49 64425242
Haemorrhage 16.97 10.20 41 73400 79310 64345981
Depressed level of consciousness 16.88 10.20 154 73287 81282 64344009
International normalised ratio increased 16.86 10.20 41 73400 79126 64346165
Exposure during pregnancy 16.72 10.20 40 73401 77635 64347656
Product dose omission issue 16.68 10.20 313 73128 194434 64230857
Non-cardiogenic pulmonary oedema 16.66 10.20 13 73428 1295 64423996
Photosensitivity reaction 16.62 10.20 52 73389 18121 64407170
Temperature intolerance 16.61 10.20 32 73409 8223 64417068
Post-traumatic stress disorder 16.34 10.20 22 73419 4183 64421108
Myocardial infarction 16.34 10.20 116 73325 165705 64259586
Alopecia 16.28 10.20 116 73325 165574 64259717
Aggression 16.19 10.20 99 73342 46133 64379158
Skin lesion 16.00 10.20 83 73358 36399 64388892
Poor feeding infant 15.80 10.20 6 73435 137 64425154
Hypercapnic coma 15.54 10.20 8 73433 384 64424907
Dyspnoea 15.52 10.20 665 72776 718009 63707282
Blood creatinine increased 15.40 10.20 91 73350 135691 64289600
Derailment 15.37 10.20 5 73436 71 64425220
Gastrointestinal haemorrhage 15.37 10.20 88 73353 132224 64293067
Haematoma 15.35 10.20 18 73423 46232 64379059
Hyperleukocytosis 15.30 10.20 15 73426 2025 64423266
Polymicrogyria 15.26 10.20 3 73438 3 64425288
Pancreatitis 15.15 10.20 118 73323 59489 64365802
Rash erythematous 15.09 10.20 101 73340 48532 64376759
Dementia 15.08 10.20 55 73386 20711 64404580
Cerebral disorder 15.07 10.20 22 73419 4507 64420784
Lip erythema 14.97 10.20 6 73435 159 64425132
Toxic skin eruption 14.80 10.20 52 73389 19232 64406059
Cerebral haemorrhage 14.79 10.20 22 73419 51068 64374223
Blood immunoglobulin E increased 14.77 10.20 20 73421 3824 64421467
Off label use 14.61 10.20 581 72860 632225 63793066
Muscle injury 14.43 10.20 6 73435 26431 64398860
Tremor 14.38 10.20 243 73198 147987 64277304
Face oedema 14.28 10.20 61 73380 24700 64400591
Alpha 1 globulin increased 14.28 10.20 5 73436 90 64425201
Wrong technique in device usage process 14.25 10.20 17 73424 2865 64422426
Pancytopenia 14.24 10.20 100 73341 143209 64282082
Clonus 14.07 10.20 25 73416 6042 64419249
Cardiac failure congestive 14.04 10.20 89 73352 130491 64294800
Substance abuse 14.00 10.20 32 73409 9260 64416031
Lymphomatoid papulosis 13.93 10.20 7 73434 319 64424972
Aplastic anaemia 13.82 10.20 41 73400 13879 64411412
Injection site induration 13.72 10.20 31 73410 8901 64416390
Peripheral circulatory failure 13.72 10.20 9 73432 682 64424609
Pupillary reflex impaired 13.37 10.20 17 73424 3056 64422235
Papule 13.25 10.20 25 73416 6325 64418966
Restless arm syndrome 13.23 10.20 4 73437 44 64425247
Tardive dyskinesia 13.16 10.20 31 73410 9147 64416144
Infective pulmonary exacerbation of cystic fibrosis 12.93 10.20 36 73405 11760 64413531
Mental disorder 12.90 10.20 62 73379 26383 64398908
Bladder dilatation 12.74 10.20 13 73428 1841 64423450
Administration related reaction 12.71 10.20 5 73436 126 64425165
Cerebrovascular accident 12.71 10.20 98 73343 137485 64287806
Acute myocardial infarction 12.68 10.20 39 73402 69679 64355612
Anion gap 12.67 10.20 13 73428 1854 64423437
Arthralgia 12.49 10.20 396 73045 441864 63983427
Breast adenoma 12.41 10.20 4 73437 55 64425236
Dyskinesia 12.34 10.20 82 73359 39306 64385985
Mental status changes 12.34 10.20 115 73326 61047 64364244
Initial insomnia 12.29 10.20 23 73418 5781 64419510
Autonomic nervous system imbalance 12.23 10.20 19 73422 4113 64421178
Sensation of blood flow 12.16 10.20 4 73437 59 64425232
Transverse sinus thrombosis 12.13 10.20 8 73433 612 64424679
Rash pruritic 12.12 10.20 109 73332 57295 64367996
Parkinsonism 12.12 10.20 40 73401 14333 64410958
Myelosuppression 12.08 10.20 6 73435 23824 64401467
Skin exfoliation 12.05 10.20 90 73351 44795 64380496
Hallucination, visual 11.98 10.20 63 73378 27771 64397520
Sensory integrative dysfunction 11.98 10.20 3 73438 15 64425276
Apallic syndrome 11.95 10.20 9 73432 850 64424441
Arthritis 11.87 10.20 52 73389 83762 64341529
Vaginal lesion 11.87 10.20 5 73436 151 64425140
Vasculitis 11.83 10.20 3 73438 18092 64407199
Alpha 2 globulin increased 11.74 10.20 5 73436 155 64425136
Hallucination, olfactory 11.74 10.20 7 73434 448 64424843
Mixed dementia 11.73 10.20 6 73435 284 64425007
Osteonecrosis of jaw 11.67 10.20 17 73424 39808 64385483
Steal syndrome 11.67 10.20 3 73438 17 64425274
Dermatitis 11.65 10.20 46 73395 17983 64407308
Multiple fractures 11.65 10.20 23 73418 6017 64419274
Administration site erythema 11.62 10.20 5 73436 159 64425132
Emotional disorder of childhood 11.52 10.20 3 73438 18 64425273
Superior mesenteric artery syndrome 11.48 10.20 5 73436 164 64425127
Wound secretion 11.42 10.20 21 73420 5211 64420080
Burnout syndrome 11.39 10.20 6 73435 302 64424989
Victim of homicide 11.26 10.20 5 73436 172 64425119
Retrograde amnesia 11.15 10.20 7 73434 492 64424799
Iron deficiency 11.13 10.20 25 73416 7152 64418139
Clostridium difficile infection 11.03 10.20 15 73426 36148 64389143
Erythema 11.03 10.20 285 73156 186785 64238506
Electric shock sensation 10.90 10.20 6 73435 330 64424961
Pharyngeal dyskinesia 10.89 10.20 3 73438 23 64425268
Leukopenia 10.88 10.20 69 73372 101173 64324118
White blood cell count decreased 10.88 10.20 121 73320 157716 64267575
Acute generalised exanthematous pustulosis 10.86 10.20 38 73403 14020 64411271
Adenoidectomy 10.85 10.20 4 73437 84 64425207
Thyroiditis acute 10.77 10.20 5 73436 191 64425100
Knee arthroplasty 10.69 10.20 9 73432 26990 64398301
Postural orthostatic tachycardia syndrome 10.69 10.20 7 73434 529 64424762
Emotional distress 10.68 10.20 74 73367 35964 64389327
Fatigue 10.66 10.20 722 72719 748008 63677283
Diabetic ketoacidosis 10.58 10.20 11 73430 29834 64395457
Tonsillar hypertrophy 10.58 10.20 10 73431 1291 64424000
Agoraphobia 10.56 10.20 7 73434 540 64424751
Cardiac failure 10.56 10.20 98 73343 132275 64293016
Dysuria 10.54 10.20 83 73358 41974 64383317
Mood altered 10.51 10.20 41 73400 15938 64409353
Sinusitis 10.40 10.20 111 73330 145817 64279474
Pain of skin 10.33 10.20 29 73412 9518 64415773
Interstitial lung disease 10.30 10.20 67 73374 97665 64327626
Liver function test abnormal 10.26 10.20 34 73407 59367 64365924

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eyelid haemangioma 20.86 17.91 3 6 9 84660

Pharmacologic Action:

SourceCodeDescription
ATC N05BB01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Diphenylmethane derivatives
ATC N05BB51 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Diphenylmethane derivatives
FDA MoA N0000000207 Histamine Receptor Antagonists
MeSH PA D000982 Antipruritics
MeSH PA D003879 Dermatologic Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:50177 dermatologic agent
CHEBI has role CHEBI:59683 antipruritic drugs
CHEBI has role CHEBI:149553 anticoronaviral drug
FDA EPC N0000175750 Antihistamine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Atopic dermatitis indication 24079001 DOID:3310
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Severe Pruritus off-label use
Tachyarrhythmia contraindication 6285003
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Shock contraindication 27942005
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Third trimester pregnancy contraindication 41587001
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Multiple organ failure contraindication 57653000
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Open-angle glaucoma contraindication 84494001 DOID:1067
Seizure disorder contraindication 128613002
Cystic fibrosis contraindication 190905008 DOID:1485
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Sepsis syndrome contraindication 238150007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Continuous fever contraindication 271751000
Smoking cessation assistance contraindication 384742004
Angle-closure glaucoma contraindication 392291006 DOID:13550
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Smokes tobacco daily contraindication 449868002
Severe Hypoxemia contraindication
Theophylline Toxicity contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.53 Basic
pKa2 3.53 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.70 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR Ki 6.42 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.30 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.41 WOMBAT-PK
Envelope glycoprotein gp160 Viral envelope protein IC50 5.20 CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Unclassified IC50 5.20 CHEMBL

External reference:

IDSource
4019782 VUID
N0000147873 NUI
D00672 KEGG_DRUG
4017874 VANDF
4017875 VANDF
4019782 VANDF
C0020404 UMLSCUI
CHEBI:5818 CHEBI
CHEMBL1201007 ChEMBL_ID
CHEMBL896 ChEMBL_ID
CHEMBL3186993 ChEMBL_ID
CHEMBL1200467 ChEMBL_ID
DB00557 DRUGBANK_ID
D006919 MESH_DESCRIPTOR_UI
3658 PUBCHEM_CID
7199 IUPHAR_LIGAND_ID
599 INN_ID
2192-20-3 SECONDARY_CAS_RN
30S50YM8OG UNII
154987 RXNORM
4857 MMSL
4858 MMSL
4859 MMSL
6478 MMSL
7094 MMSL
d00907 MMSL
001451 NDDF
001452 NDDF
001453 NDDF
372856003 SNOMEDCT_US
80165005 SNOMEDCT_US
83933007 SNOMEDCT_US
83945003 SNOMEDCT_US
10246-75-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5410 CAPSULE 25 mg ORAL NDA 15 sections
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5420 CAPSULE 50 mg ORAL NDA 15 sections
Vistaril HUMAN PRESCRIPTION DRUG LABEL 1 0069-5440 SUSPENSION 25 mg ORAL NDA 15 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5060 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5060 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5061 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5061 TABLET, FILM COATED 25 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5062 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5062 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1670 CAPSULE 25 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1671 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1803 CAPSULE 25 mg ORAL ANDA 13 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0115-1804 CAPSULE 50 mg ORAL ANDA 13 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-4822 SYRUP 10 mg ORAL ANDA 14 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0613 CAPSULE 25 mg ORAL ANDA 14 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0613 CAPSULE 25 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0615 CAPSULE 50 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0615 CAPSULE 50 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0674 CAPSULE 25 mg ORAL ANDA 14 sections
hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0674 CAPSULE 25 mg ORAL ANDA 14 sections
Hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0676 CAPSULE 50 mg ORAL ANDA 14 sections
Hydroxyzine pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0185-0676 CAPSULE 50 mg ORAL ANDA 14 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9877 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 9 sections
Hydroxyzine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9878 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 9 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-1617 TABLET, FILM COATED 25 mg ORAL ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-4201 INJECTION, SOLUTION 25 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5601 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5602 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-5610 INJECTION, SOLUTION 50 mg INTRAMUSCULAR ANDA 11 sections
Hydroxyzine Pamoate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0302 CAPSULE 50 mg ORAL ANDA 13 sections